Literature DB >> 14610624

Comparison of chlorzoxazone one-sample methods to estimate CYP2E1 activity in humans.

Iza Kramer1, Kim Dalhoff, Jens O Clemmesen, Steffen Loft, Henrik E Poulsen.   

Abstract

OBJECTIVE: Comparison of a one-sample with a multi-sample method (the metabolic fractional clearance) to estimate CYP2E1 activity in humans.
METHODS: Healthy, male Caucasians ( n=19) were included. The multi-sample fractional clearance (Cl(fe)) of chlorzoxazone was compared with one-time-point clearance estimation (Cl(est)) at 3, 4, 5 and 6 h. Furthermore, the metabolite/drug ratios (MRs) estimated from one-time-point samples at 1, 2, 3, 4, 5 and 6 h were compared with Cl(fe).
RESULTS: The concordance between Cl(est) and Cl(fe) was highest at 6 h. The minimal mean prediction error (MPE) of Cl(est) as a percentage of actual mean Cl(fe) was -4.2% at 6 h. Furthermore, regarding Cl(fe), there was a negligible difference ( P=0.56) of bias between Cl(est) at 3 h (MPE=-8.9%) and 6 h (MPE=-4.2%). The best concordance between MR and Cl(fe) was found at 3 h (r=0.74; P<0.001).
CONCLUSION: All three single-dose-sample estimates, Cl(est) at 3 h or 6 h, and MR at 3 h, can serve as reliable markers of CYP2E1 activity. The one-sample clearance method is an accurate, renal function-independent measure of the intrinsic activity; it is simple to use and easily applicable to humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610624     DOI: 10.1007/s00228-003-0695-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1.

Authors:  R Peter; R Böcker; P H Beaune; M Iwasaki; F P Guengerich; C S Yang
Journal:  Chem Res Toxicol       Date:  1990 Nov-Dec       Impact factor: 3.739

2.  Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure.

Authors:  R F Frye; A Adedoyin; K Mauro; G R Matzke; R A Branch
Journal:  J Clin Pharmacol       Date:  1998-01       Impact factor: 3.126

3.  High-performance liquid chromatography with electrochemical detection of chlorzoxazone and its hydroxy metabolite in serum using solid-phase extraction.

Authors:  J T Stewart; H K Carter
Journal:  J Chromatogr       Date:  1986-07-11

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation.

Authors:  H Yamazaki; Z Guo; F P Guengerich
Journal:  Drug Metab Dispos       Date:  1995-03       Impact factor: 3.922

6.  Optimal sampling times for minimum variance of clearance determination.

Authors:  M Døssing; A Vølund; H E Poulsen
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

7.  Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans.

Authors:  D Lucas; R Ferrara; E Gonzalez; P Bodenez; A Albores; M Manno; F Berthou
Journal:  Pharmacogenetics       Date:  1999-06

8.  Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics.

Authors:  C Girre; D Lucas; E Hispard; C Menez; S Dally; J F Menez
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

9.  Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1.

Authors:  E D Kharasch; K E Thummel; J Mhyre; J H Lillibridge
Journal:  Clin Pharmacol Ther       Date:  1993-06       Impact factor: 6.875

10.  Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms.

Authors:  R B Kim; D O'Shea
Journal:  Clin Pharmacol Ther       Date:  1995-06       Impact factor: 6.875

View more
  1 in total

1.  Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model.

Authors:  Jia Li; Hai-Fang Guo; Can Liu; Zeyu Zhong; Li Liu; Xiao-Dong Liu
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.